Receptores hormonales y de estrógenos en la mujer transexual (página 2)

13. Dehm SM, Tindall DJ: Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol 2007, 21:2855-2863.

14. Denton RR, Notides AC. Estrogen receptor phosphorylation. Hormonal dependence and consequence on specific DNA binding. J Biol Chem 1992;267:7263–7268•

15. Díaz, B. N. 2004. Bioquímica Básica de las Hormonas Esteroideas: Biología y Clínica del Cáncer. Biocáncer 2. pp 1-22.

16.  Diez-Perez A. Selective estrogen receptor moduladors(SERMS).Arq Bras Endocrinol Metab 2006;50:720-734.

17. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M & Gustafsson JA 1997 Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern.Journal of Clinical Endocrinology and Metabolism824258–4265

18. Fuqua SA, Schiff R, Parra I, Friedrichs WE, Su JL, McKee DD, Slentz-Kesler K, Moore LB, Willson TM, Moore JT. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res 1999;59:5425-5428

19. Gelmann EP: Molecular biology of the androgen receptor. J Clin Oncol 2002, 20:3001-3015.

20. Grossmann ME, Huang H, Tindall DJ: Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001, 93:1687-1697.

21. Gustafsson, J. A. 1999. Estrogen receptor ßeta- a new dimension in estrogen mechanism of action. Journal of Endocrinology. 163, 379 – 383.

22. Haelens A, Tanner T, Denayer S, Callewaert L, Claessens F: The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res 2007, 67:4514-4523.

23. Hart, S. M. 2002. Modulation of nuclear receptor dependent transcription. Biol Res. 35: 295 – 303.

24. Heinlein CA, Chang C: Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002, 23:175-200.

25. Heinlein CA, Chang C: Androgen receptor in prostate cancer. Endocr Rev 2004, 25:276-308

26. Herrera, E. 1991. Hormonas Esteroideas, en: Bioquímica. Biología molecular y bioquímica fisiológica, 2ª edición, vol II. McGraw-Hill/ Interamericana. España: 1161 – 1172.

27. Hillier SG, Anderson RA, Williams AR, Tetsuka M. Expression of oestrogen receptor alpha and beta in cultured human ovarian surface epithelial cells. Mol Hum Reprod 1998;4:811-815

28.  Hsieh CL, Cai C, Giwa A et al.: Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells. J Mol Endocrinol 2008, 41:13-23.

29. Huch K.M., Elam, M.B., Chesney, C.M. Oral contraceptive Steroids induce plateletcoagulant hyperactivity. Thromb.Res.1:41 -50, 1987

30. Katzung, B. "Farmacología Básica y Clínica" 2ª edic. 1986

31. Kingle, c. m. 2000. Estrogen receptor interaction with co-activators and co-repressors. Steroids. May; 65 (5): 227 – 251Madrid, España: 544 – 547 y 596 – 612.

32. Klein–Hitpass L, Ryffel GU, Heitlinger E, Cato AC. A sindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor. Nucleic Acids Res1988;16:647–663.

33. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Research 2001;2905–2919•

34. Klinge CM. Estrogen receptor interaction with co-activators and co-repressors. Steroid 2000;65:227-251•

35. Krishnan V, Heath H y Bryant UH. Mechanism of action of estrogen and selective estrogen receptors modulators. Vitamins and Hormones 2001;60:123-147

36. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S & Gustafsson JA 1996 Cloning of a novel receptor expressed in rat prostate and ovary.PNAS93 5925–5930

37. Kumar R, Thompson EB. Transactivation functions of the No-terminal domains of nuclear hormone receptors: protein folding and coactivator interactions. Mol Endocrinol 2003;17:1-10•

38. Luke MC, Coffey DS: The male sex accessory tissues. Structure, androgen action, and physiology. In The physiology of reproduction. Vol. 1 Edited by Knobil E, Neill JD. Raven Press, New York; 1994:1435-1487.

39. Marin R, Guerra B, Alonso R, Ramirez CM, Diaz M. Estrogen activates classical and alternative mechanisms to orchestrate neuroprotection. Curr Neurovasc Res 2005; 2(4): 287-301.

40. Mathews, c. k., van holde, K.E. 1999. Mecanismo de Acción Hormonal, en: Bioquímica, segunda edición. McGraw-Hill/Interamericana. España: 918 – 939.

41. Mathews, c. k., van holde, k.e. 1999. Metabolismo de los Esteroides, en: Bioquímica, segunda edición. McGraw-Hill/Interamericana. España: 749 – 760

42. Matsumoto T, Takeyama K, Sato T, Kato S: Study of androgen receptor functions by genetic models. J Biochem 2005, 138:105-110.

43. Montgomery r., Conway t. w., Spector a. a., chappell D. 1998. Endocrinología Molecular: Señalización Celular mediante Hormonas y Neurotransmisores. Hormonas que actúan en el Interior de la Célula, en: Bioquímica, casos y texto, sexta edición. Harcourt-Brace,

44. Olefsky, J.M. 2001. Nuclear receptor minireview series. J. Biol. Chem. 276 (40): 36863 – 4.

45. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ & Scanlan TS 1997 Differential ligand activation of estrogen receptors ER alpha and ERbeta at AP1 sites.Science2771508–1510.

46. Pelletier G & El-Alfy M 2000 Immunocytochemical localization of estrogen receptors alpha and beta in the human reproductive organs.Journal of Clinical Endocrinology and Metabolism854835–4840

47. Revankar CM, Cimino CF, Sklar LA, Arteburn JB, Prossnitz ER. A trans-membrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307(5715): 1625-1630.

48. Reyes-Fuentes, A. and Veldhuis, J D 1993. Neuroendocrine physiology of the normal male gonadal axis. In Endocrinology and Metabolism Clinics of North America. Edited by Velduis, J D Philadelphia, PA: W.B. Saunders Co., 22:93-124

49. Shi Y, Downes M, Xie W, Kao HY, Ordentlich P, Tsai CC, Hon M, Evans RM. Sharp, an inducible cofactor that integrates nuclear receptor repression and activation. Genes and Development 2001;15:1140–1151

50. So AI, Hurtado-Coll A, Gleave ME: Androgens and prostate cancer. World J Urol 2003, 21:325-337.

51. Suzuki H, Ueda T, Ichikawa T, Ito H: Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 2003, 10:209-216.

52. Taplin ME, Ho SM: Clinical review 134: The endocrinology of prostate cancer. J Clin Endocrinol Metab 2001, 86:3467-3477.

53. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol. 1994;8:21–30•

54. Weigel NL, Moore NL: Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol Endocrinol 2007, 21:2311-2319.

55. Weigel NL, Zhang Y. Ligand-independent activation of steroid hormone receptors. J Mol Med 1998;76:469-479•

56. Williams, Textbook of Endocrinology, 8th edition. Edited by Wilson, J D and Foster, D W Philadelphia, PA: W B Saunders Co., 978 – 995, 1992.

57. Wise PM, Dubal DB, Rau SW, Brown CM, Suzuki S. Are estrogens protective or risk factors in brain injury and neuro degeneration? Reevaluation after the women"s health initiative. Endosc Rev 2005; 26(3): 308-312.

58. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251-306.

59. Xing N, Chen Y, Mitchell SH, Young CY: Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 2001, 22:409-414.

60. Zhu ML, Kyprianou N: Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008, 15:841-849.